Published in Obesity and Diabetes Week, February 21st, 2005
The data were presented at the second annual Gastrointestinal Cancers Symposium in Hollywood, Florida. According to the companies, Tarceva is the first drug shown in a phase III trial to prolong survival when added to the standard of care (gemcitabine)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week